Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Recurrence × pembrolizumab × Clear all

Phase

Status

Sponsor Class

OTHER 30 INDUSTRY 14 OTHER_GOV 1 NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Head and Neck Neoplasms 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Ovarian Diseases 1 Neoplasms, Glandular and Epithelial 1 Gliosarcoma 1 Glioblastoma 1 Genital Neoplasms, Female 1 Endometrial Neoplasms 1 Efficacy, Team 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumours 1 Advanced Solid Tumor 1 Adrenocortical Carcinoma 1

Interventions

Surgical Procedures, Operative 2 Dexamethasone 2 temoporfin 1 pomalidomide 1 pembrolizumab 1 nimotuzumab 1 liposomal doxorubicin 1 ledipasvir 1 ibrutinib 1 Vinorelbine 1 Tomography, X-Ray Computed 1 Thalidomide 1 Sofosbuvir 1 Rituximab 1 Ribavirin 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1 Mitoxantrone 1 Mastectomy 1 Irinotecan 1 Immunotherapy, Adoptive 1 Hematologic Tests 1 Drug Therapy 1 Docetaxel 1 Diagnostic Imaging 1 Dermoscopy 1 Cyclophosphamide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06670911 2025-02-24

ACCESS-I

Instituto Nacional de Cancer, Brazil

Phase 2 Recruiting

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡